News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Moberg Derma and PharmaPlan Sign Agreement for NALOX/EMTRIX in South Africa



3/27/2012 7:34:30 AM

STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News:

Moberg Derma AB (STO:MOB) has entered into a distribution agreement with Pharmaplan (Pty) Ltd. for Nalox™//Emtrix® – for discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement Pharmaplan is granted exclusive rights to market and sell Nalox™ /Emtrix® in South Africa. Moberg Derma assumes production and supply responsibility.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES